Innovative Food Science & Emerging Technologies, Год журнала: 2024, Номер unknown, С. 103900 - 103900
Опубликована: Дек. 1, 2024
Язык: Английский
BMC Gastroenterology, Год журнала: 2025, Номер 25(1)
Опубликована: Янв. 27, 2025
An exploration of the influence probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity prognosis in patients metastatic colorectal carcinoma. This was a quasi-experimental study. During March 2019 to 2020, 96 carcinoma were arbitrarily classified into control group (n = 48) intervention 48). The received only inhibitors or chemotherapy, while plus probiotic therapy. Survival complication rates after 6 months, 12 months 2 years treatment calculated. Intestinal barrier function quality life analyzed before treatment. Ninety-six recorded at follow-up demonstrating superior survival D-lactate diamine oxidase (DAO) levels elevated treatment, smaller elevations (P < 0.05). Bifidobacterium Lactobacillus remarkably higher compared prior following therapy amount Enterococcus Escherichia coli obviously lower pre-treatment groups CD3+, CD4+, CD4+/CD8+ found be 0.05), CD8+ reduced All dimensions QLQC-30 scale incidence complications such as nausea vomiting, loss appetite, bloating diarrhea considerably Immune regimens can enhance combination therapeutic strategy balance imbalanced flora, improve lessen adverse events, so it is worthy clinical application reactions.
Язык: Английский
Процитировано
1
Probiotics and Antimicrobial Proteins, Год журнала: 2025, Номер unknown
Опубликована: Фев. 15, 2025
Язык: Английский
Процитировано
0
European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177410 - 177410
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Antibiotics, Год журнала: 2025, Номер 14(3), С. 264 - 264
Опубликована: Март 5, 2025
With nearly half of colorectal cancer (CRC) patients diagnosed at advanced stages where surgery alone is insufficient, chemotherapy remains a cornerstone for this treatment. To prevent infections and improve outcomes, antibiotics are often co-administered. However, chemotherapeutic interactions with the gut microbiota cause significant non-selective toxicity, affecting not only tumor normal epithelial cells but also microbiota. This toxicity triggers bacterial SOS response loss microbial diversity, leading to mutations dysbiosis. Consequently, pathogenic overgrowth systemic increase, necessitating broad-spectrum intervention. review underscores how prolonged antibiotic use during chemotherapy, combined chemotherapy-induced mutations, creates selective pressures that drive de novo antimicrobial resistance (AMR), allowing resistant bacteria dominate gut. compromises treatment efficacy elevates mortality risk. Restoring diversity may mitigate therapeutic emerging strategies, such as fecal transplantation (FMT), probiotics, prebiotics, show considerable promise. Given global threat posed by treatment, prioritizing stewardship essential optimizing preventing in CRC undergoing chemotherapy. Future research should aim minimize chemotherapy’s impact on develop targeted interventions restore affected
Язык: Английский
Процитировано
0
Innovative Food Science & Emerging Technologies, Год журнала: 2024, Номер unknown, С. 103900 - 103900
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0